Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer

References

• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76; PMID:18160686; http://dx.doi.org/10.1056/NEJMoa072113
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239-47; PMID:20498403; http://dx.doi.org/10.1200/JCO.2008.21.6457
   PubMed Web of Science ®Google Scholar
• Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29:1252-60; PMID:21383283; http://dx.doi.org/10.1200/JCO.2010.28.0982
   PubMed Web of Science ®Google Scholar
• Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15(12):1351-60; Published online on 28 September; PMID:25273343; http://dx.doi.org/10.1016/S1470-2045(14)70444-9
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014; (11):1269-78; Published online on 28 September; PMID:25273342; http://dx.doi.org/10.1016/S1470-2045(14)70439-5
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116:2610-21; PMID:17016557; http://dx.doi.org/10.1172/JCI24612
   PubMed Web of Science ®Google Scholar
• Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998; 95:10820-5; PMID:9724788; http://dx.doi.org/10.1073/pnas.95.18.10820
   PubMed Web of Science ®Google Scholar
• Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 2003; 98:2125-32; PMID:14601081; http://dx.doi.org/10.1002/cncr.11764
   PubMed Web of Science ®Google Scholar
• Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18:1423-31; PMID:10735889
   PubMed Web of Science ®Google Scholar
• Fabi A, Russillo M, Ferretti G, Metro G, Nistic∫ C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, et al. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012; 12:482; PMID:23083011; http://dx.doi.org/10.1186/1471-2407-12-482
   PubMed Web of Science ®Google Scholar
• Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nistic∫ C, Russillo M, et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011; 12:30-54; PMID:21569417
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial—arimidex study group. J Clin Oncol 2000; 18:3758-67; PMID:11078488
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-57; PMID:11078487
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606; PMID:11352951
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-9; PMID:12775735; http://dx.doi.org/10.1200/JCO.2003.04.194
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol 2008; 26(30):4883-90; PMID:18794551; http://dx.doi.org/10.1200/JCO.2007.14.4659
   PubMed Web of Science ®Google Scholar